<DOC>
	<DOCNO>NCT02719912</DOCNO>
	<brief_summary>This study evaluate MValve mitral prosthesis conjunction Lotus transcatheter heart valve ( THV ) mitral valve replacement subject high risk conventional mitral valve replacement repair surgery .</brief_summary>
	<brief_title>Mitral Valve Replacement With MValve Dock Lotus</brief_title>
	<detailed_description>This study prospective first man feasibility study intend evaluate preliminary safety effectiveness MValve Mitral Dock Lotus transcatheter heart valve mitral valve replacement subject high risk surgical valve repair replacement . The surgical technique adapts valve-in-valve approach mitral replacement degenerate mitral prosthesis fail native mitral valve . The MValve Dock design provide structural platform within mitral annulus Lotus THV implant secure fashion mitral annulus . The investigational device anchor mitral annulus commissure , spar native valve leaflet sub annular apparatus . This study design treat subject moderate-to-severe MR deem candidate mitral valve surgery .</detailed_description>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<criteria>Symptomatic ≥3+ degenerative functional mitral regurgitation either ischemic nonischemic etiology base qualify echocardiography obtain within 90 day prior procedure . New York Heart Association ( NYHA ) Functional Class III IV . High risk conventional open mitral valve repair replacement surgery consideration site Heart Team . Left Ventricular Ejection Fraction ( LVEF ) ≥30 % within 30 day prior procedure . Mitral valve annular commissure commissure ( C/C ) dimension 3035 mm echocardiography . Left atrial diameter &lt; 5.5 cm echocardiography Prior mitral valve replacement repair surgery . Prior transapical surgery . Severe aortic tricuspid valve disease . Severe symptomatic carotid stenosis ( &gt; 70 % ultrasound ) . ACC/AHA Stage D heart failure . Hypertrophic cardiomyopathy , restrictive cardiomyopathy , constrictive pericarditis , structural heart disease cause heart failure dilate cardiomyopathy either ischemic nonischemic etiology . Infiltrative cardiomyopathy ( amyloidosis , hemochromatosis , sarcoidosis ) . Physical evidence rightsided congestive heart failure echocardiographic evidence moderate severe right ventricular dysfunction . Severe mitral annular calcification . Glomerular filtration rate ( GFR ) &lt; 30 . Hemodynamic instability define systolic pressure &lt; 90 mm Hg without afterload reduction , cardiogenic shock , need inotropic support intraaortic balloon pump hemodynamic support device , mechanical heart assistance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>